Revolution Medicines (RVMD) Cash & Equivalents (2018 - 2026)

Revolution Medicines' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $440.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 32.19% year-over-year to $440.9 million; the TTM figure through Mar 2026 stood at $440.9 million (up 32.19% YoY), while the FY2025 annual figure was $383.7 million, down 29.34% from the prior year.
• Cash & Equivalents was $440.9 million for Q1 2026 at Revolution Medicines, up from $383.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $696.1 million in Q4 2023 to a low of $97.7 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $323.1 million across 5 years, with a median of $333.6 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents plunged 72.22% in 2022, then soared 337.43% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $161.4 million in 2022, then soared by 331.29% to $696.1 million in 2023, then retreated by 21.99% to $543.1 million in 2024, then dropped by 29.34% to $383.7 million in 2025, then climbed by 14.9% to $440.9 million in 2026.
• The last three Cash & Equivalents figures came in at $440.9 million (Q1 2026), $383.7 million (Q4 2025), and $217.4 million (Q3 2025), per Business Quant data.